zibotentan

Known as: 3-Pyridinesulfonamide, N-(3-methoxy-5-methylpyrazinyl)-2-(4-(1,3,4-oxadiazol-2-yl)phenyl)-, N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pridine-3- sulfonamide 
An orally available selective antagonist of the endothelin-A (ET-A) receptor with potential antineoplastic activity. Zibotentan binds selectively to… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2015
051020092015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
PURPOSE As part of the ENTHUSE (Endothelin A Use) program, the efficacy and safety of zibotentan (ZD4054), an oral specific… (More)
Is this relevant?
2013
2013
Background:Standard treatment options are limited for the management of non-metastatic castration-resistant prostate cancer (CRPC… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2013
2013
Endothelin 1 (ET-1) is overexpressed in cancer, contributing to disease progression. We previously showed that ET-1 stimulated… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
BACKGROUND Endothelin-1 and the endothelin A (ET(A) ) receptor have been implicated in prostate cancer progression in bone. This… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE Emerging evidence suggests molecular and phenotypic association between chemoresistance and epithelial-mesenchymal… (More)
Is this relevant?
2011
2011
117 Background: Endothelin-1 and the endothelin A (ETA) receptor have been implicated in prostate cancer progression in bone… (More)
Is this relevant?
2011
2011
BACKGROUND Zibotentan (ZD4054) is a specific endothelin A (ETA) receptor antagonist being investigated for the treatment of… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
Highly Cited
2010
Highly Cited
2010
OBJECTIVES To report the final analysis of a Phase II trial, which investigated the safety and efficacy of the specific… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2010
2010
In human ovarian carcinoma, the endothelin-1 (ET-1) / endothelin A receptor (ETAR) axis is overexpressed, correlating with tumor… (More)
  • figure 1
  • figure 2
  • table 1
Is this relevant?
2009
2009
Purpose To assess the maximum well-tolerated dose (MWTD), dose limiting toxicity (DLT), pharmacokinetics (PK) and… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?